In a nutshell This study wanted to see how well the medication afatinib (Giotrif) works in real-life settings, outside of clinical trials in patients with advanced non-small cell lung cancer (NSCLC). The study found that patients treated with afatinib had a good response rate and survival. Some background There are many...
Read MoreOngoing treatment(s)-Biological therapy Posts on Medivizor
Evaluating immune-related side effects associated with pembrolizumab.
In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...
Read MoreEnding trastuzumab treatment in patients with HER2-positive metastatic breast cancer who are in radiological complete remission
In a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission. This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...
Read MoreEpidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for lung cancer
In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with non-small cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some...
Read MoreEpidermal growth factor ointment improves the treatment of skin side effects in patients receiving treatment for colorectal cancer
In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with colorectal cancer receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some background...
Read MoreIs there an increased risk of fatigue and anemia after treatment with olaparib?
In a nutshell This study investigated the risk of fatigue and anemia with olaparib (Lynparza) treatment. The study found that there is an increased risk of fatigue and anemia with this treatment. Some background Breast cancer (BC) is the most common cancer affecting women. Some types of BC are caused by genetic mutations. These...
Read MoreSearching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.
In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...
Read MoreStopping TKI treatment in chronic myeloid leukemia
In a nutshell This study was an update on the guidelines of stopping tyrosine kinase inhibitor (TKI) therapy in the treatment of chronic myeloid leukemia (CML). New guidelines confirm the safety of stopping TKI therapy in patients with CML. Some background Chronic myeloid leukemia is often treated with TKI therapy. These are drugs which...
Read MoreLooking for patients with lung cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with solid tumors, including lung cancer. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of limited...
Read MoreRate of deep molecular response in chronic myeloid leukemia treated with nilotinib
In a nutshell This study aimed to investigate the rate of deep molecular response in patients with newly diagnosed chronic myeloid leukemia who were treated with nilotinib. This study concluded that good molecular response rates are seen in these patients. Some background Molecular response (MR) is a measure of the levels of BCR-ABL1 gene in leukemia...
Read MoreEffectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia
In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...
Read MoreCan monitoring minimal residual disease levels in CLL predict outcomes?
In a nutshell This study assessed if monitoring the minimal residual disease (MRD) levels in chronic lymphocytic leukemia (CLL) can help guide future treatment strategies. This study concluded MRD monitoring can be used to predict outcomes and may help guide future treatment choices. Some background Chronic lymphocytic leukemia is a cancer of...
Read More
